Little biotech developing Genentech castoff drug hits hurdle in glioblastoma platform trial
When the Global Coalition for Adaptive Research brought the PI3K inhibitor paxalisib into its platform trial for glioblastoma in early 2021, the drug’s developer — Australia’s Kazia Therapeutics — was upbeat about how success in the trial, dubbed GBM AGILE, may speed up the process of finding effective therapies and “pave the way to providing a new treatment in this disease.”
But paxalisib may now be getting weeded out from that study.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.